Table of contents

  • Brand Names
  • Drug Combinations
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Toxicological Effects
  • Genes that may be involved
  • Drug Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Hipracin, Intertocine, Oxytocin, Syntocinon; Belgium: Syntocinon; Bulgaria: Oxytocin; Cyprus: Oxitone, Piton; Czech Republic: Oxytocin; Denmark: Syntocinon; Estonia: Oxitocin; Finland: Syntocinon; France: Syntocinon; Germany: Synpitan, Syntocinon; Greece: Oxytocin; Hungary: Oxytocin; Ireland: Syntocinon; Italy: Ossitocina, Syntocinon; Luxembourg: Syntocinon; Netherlands: Syntocinon; Poland: Oxytocin, Sandopart; Portugal: Oxitocina, Syntocinon; Romania: Oxitocin; Slovakia: Oxytocin; Slovenia: Syntocinon; Spain: Syntocinón; Sweden: Syntocinon; UK: Syntocinon.

North America

Canada: Oxytocin; USA: Oxytocin, Pitocin.

Latin America

Argentina: Hipofisina, Ocitocina, Oxitocina, Syntocinón, Veracuril; Brazil: Naox, Orastina, Oxiton, Syntocinon; Mexico: Oxitocina, Oxitopisa, Syntocinón, Xitocín.


Japan: Atonin.

Drug combinations

Oxytocin and Ergonovine


Oxytocin: C~43~H~66~N~12~O~12~S~2~. Mw: 1007.19. CAS-50-56-6.

Pharmacologic Category

Oxytocics. (ATC-Code: H01BB02).

Mechanism of action

Indirectly stimulates contraction of uterine smooth muscle by increasing sodium permeability of uterine myofibrils. Increases contraction amplitude and frequency, which tends to decrease cervical activity, produce dilation and effacement of cervix, and transiently impede uterine blood flow. Contracts myoepithelial cells surrounding alveoli of breasts, forcing milk from alveoli into larger ducts and facilitating milk ejection. Minimal antidiuretic activity relative to vasopressin. Water intoxication possible at high doses and/or excessive electrolyte-free fluid.

Therapeutic use

Induction of labor at term. Control of postpartum bleeding. Adjunctive therapy in management of abortion.

Pregnancy and lactiation implications

Reproduction studies not conducted. When used as indicated, teratogenic effects not expected. Nonteratogenic adverse reactions reported in neonate as well as in mother. Oxytocin not indicated for use during 1^st^ or 2^nd^ trimester of pregnancy other than in relation to spontaneous or induced abortion. Excretion in breast milk unknown (use caution).

Unlabeled use


Hypersensitivity to oxytocin or any component of the formulation. Significant cephalopelvic disproportion. Unfavorable fetal positions. Fetal distress. Hypertonic or hyperactive uterus. Contraindicated vaginal delivery (invasive cervical cancer, active genital herpes, prolapse of cord, cord presentation, total placenta previa, or vasa previa). Uterine or cervical scarring from previous cesarean section or major cervical or uterine surgery.

Warnings and precautions

May produce antidiuretic effect (i.e. water intoxication and excess uterine contractions). High doses or hypersensitivity to oxytocin may cause uterine hypertonicity, spasm, tetanic contraction, or rupture of uterus. Severe water intoxication with convulsions, coma, and death associated with slow oxytocin infusion over 24 hours. To be used for medical rather than elective induction of labor.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart